Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY
Greco B. Malijan, William G. Herrington, Daniel P. Chapman(Georgetown University), Stewart Moffat(University of Oxford), Natalie Staplin(University of Oxford), Nadine Nägele(University of Zurich), Dilushi Wijayaratne(The Royal Free Hospital), Dominik Steubl(Boehringer Ingelheim (Germany)), Doreen Zhu, Roberto Pontremoli(Ospedale Policlinico San Martino), Sibylle J. Hauske(Heidelberg University), Rebecca J. Sardell(University of Miami), Colin Baigent, Katherine R. Tuttle, Martin J. Landray, Michael G. Shlipak, Christoph Wanner, Joachim H. Ix, Sarah Y.A. Ng, David Z.I. Cherney, Olivier Devuyst, Michael Hill, Richard Haynes, Michaela Petrini(University of Oxford), Parminder K. Judge, Killian Donovan(National Health Service)
Cited by 0
Related Papers
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
|Nature Genetics|2015|1.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
|Circulation|2020|282